With the recently approved rheumatoid arthritis therapies along with new therapies are sure to drive the rheumatoid arthritis therapeutics market in Asia-Pacific. The promising pipeline companies are Johnson & Johnson( J & J), GlaxoSmithKline( GSK)' s sirukumab, and Galapagos ' s filgotinib. The leading players in rheumatoid arthritis therapeutics market are AbbVie, Amgen, Amgen, Daiichi Sankyo, Biogen Idec, Genentech, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Regeneron, Sanofi, Roche and UCB.
India, Australia, China, South Korea and Japan are the leading consumers in Asia-Pacific( APAC) rheumatoid arthritis therapeutics market. Japan accounted for a majority share of the market, followed by China, Australia, India and South Korea. The introduction of biologic disease modifying antirheumatic drugs( DMARD) has helped in the growth of the rheumatoid arthritis( RA) market in Asia-Pacific tremendously over the last two decades. This growth is expected to continue at a moderate pace in the next few years.
To know more, click on the link below:
https:// www. kenresearch. com / healthcare / general-healthcare / rheumatoid-arthritistherapeutics-in-asia-pacific-markets-to-2023-novel-jak-and-il-6-receptor-inhibitors-tostimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs / 149110- 91. html
Related Reports:
https:// www. kenresearch. com / healthcare / general-healthcare / osteoarthritis-pipelinereview / 143930-91. html
https:// www. kenresearch. com / healthcare / pharmaceuticals / osteoarthritis-pipeline-reviewh2-2017 / 142124-91. html
Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales @ kenresearch. com 0124-4230204